ELN — Elanix Biotechnologies AG Income Statement
0.000.00%
Last trade - 00:00
HealthcareHighly SpeculativeMicro Cap
- €0.43m
- €0.39m
- €0.06m
2014 December 31st | R2015 December 31st | R2016 December 31st | R2017 December 31st | 2018 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | GAS | IFRS | — | — | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0.006 | 0.227 | 0.062 |
Cost of Revenue | |||||
Gross Profit | — | 0 | 0.003 | 0.085 | -0.219 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 0.015 | 3.16 | 2.33 | 3.46 | 3.74 |
Operating Profit | -0.015 | -3.16 | -2.32 | -3.24 | -3.67 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.015 | -3.17 | -2.35 | -3.51 | -3.46 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.015 | -2.79 | -1.89 | -2.99 | -3.73 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.015 | -2.79 | -1.89 | -2.99 | -3.73 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.015 | -2.79 | -1.89 | -2.99 | -3.73 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.027 | -0.356 | -0.34 | -0.455 | -0.49 |
Dividends per Share |